07:51 AM EDT, 07/16/2024 (MT Newswires) -- SciSparc ( SPRC ) said Tuesday it has filed a patent application for the composition of Palmitoylethanolamide, the active ingredient of SciSparc's ( SPRC ) CannAmide with Clearmind Medicine's ( CMND ) MEAI compound to treat metabolic syndrome and obesity.

The application was one of several filed with the US Patent and Trademark Office as part of SciSparc's ( SPRC ) current partnership with Clearmind for under-treated health challenges and invented with Yissum, Hebrew University's technology transfer company, according to SciSparc ( SPRC ).

Clearmind had filed 12 other patent applications for various compositions under their collaboration, SciSparc ( SPRC ) said.

The companies first signed a research agreement with the Hebrew University of Jerusalem in June last year to evaluate the drugmakers' combination treatment for obesity and metabolic syndrome.

SciSparc's ( SPRC ) stock rose nearly 34% in recent Tuesday premarket activity while Clearmind's shares fell more than 7%.

Price: 1.1300, Change: +0.29, Percent Change: +33.92